Conquer cancer foundation • cancer. Net • journal of clinical oncology • journal of oncology practice asco university • quality oncology practice initiative (qopi) • asco connection view sitemap a-z indexed sitemap advanced search asco sign in manage email subscriptions username: create an account why be a member? buy viagra cheap Password: remember me forgot your username or password? Asco membership directory the remember me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which asco. Org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to asco. discounted prescription viagra Org. Do not select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users. To activate the remember me option, click the empty check box when signing in to the site. The remember me functionality is deactivated at the logout. For additional information please review our privacy policy. Practice & guidelines research resources education & training public policy international affairs grants & awards multimedia press center asco home     meetings     abstracts       2006 asco annual meeting   randomized phase iii trial of capecitabine/cisplatin (xp) vs. Continuous infusion of 5-fu/cisplatin (fp) as first-line therapy in patients (pts) with advanced gastric cancer (agc): efficacy and safety results print this page sub-category: esophageal, gastric, or small bowel category: gastrointestinal (noncolorectal) cancer meeting: 2006 asco annual meeting session type and session title: oral abstract session, gastrointestinal (non-colorectal) cancer - gastroesophageal cancer abstract no: lba4018 citation: journal of clinical oncology, 2006 asco annual meeting proceedings part i. Vol 24, no. 18s (june 20 supplement), 2006: lba4018 author(s): y. Kang, w. K. Kang, d. B. Shin, j. Chen, j. Xiong, j. Wang, m. Lichinitser, m. P. Salas, t. Suarez, j. Santamaria abstract: background: the oral fluoropyrimidine capecitabine has proven efficacy and safety in colorectal and breast cancer. Phase ii data in agc suggested that xp would show comparable efficacy to a standard fp regimen, with potential safety and convenience advantages. This phase iii study evaluated xp vs. Fp in first-line agc. Methods: pts with previously untreated measurable agc received either oral capecitabine (1000mg/m2 bid d1-14) + cisplatin (80mg/m2 i. V. D1) q3w (xp arm) or 5-fu (800mg/m2/d continuous infusion, d1-5) + cisplatin (80mg/m2 i. V. D1) q3w (fp arm). Xp requires 1 day per 3 weeks in hospital; fp requires 5 days. Pts were treated until disease progression or unacceptable toxicity. Primary endpoint: non-inferiority (ni) in progression-free survival (pfs), defined as upper limit of 95% ci of hazard ratio (hr) <1. buying online viagra 4 (first test) and <1. 25 (second test). Results: from apr 03 to jan 05, 316 pts were enrolled in 46 centers/13 countries. Arms were well balanced: median age (years, range) xp (56, 26-74), fp (56, 22-73); median karnofsky ps 80 (range 70-100) in both arms; male/female (%): xp (64/36) fp (69/31). Median no. Of cycles was 5 (xp and fp). cheap viagra fast shipping Median follow-up is 22. 1 months. Primary endpoint was met: hr 0. 81 (95% ci 0. buy cheap generic viagra online 63-1. 04). Xp was superior to fp in terms of overall response rate (orr, recist). Efficacy is presented in the table. Most common treatment-related grade 3/4 adverse events (xp vs. Fp) were: neutropenia (16 vs. 19%), vomiting (7 vs. 9%), stomatitis (2 vs. 7%), diarrhea (5 vs. 5%), and anemia (5 vs. 3%). Other grade 3/4 events occurred in <5% of pts. The rate of all-grade hand-foot syndrome was low (22 vs. 4%). Conclusions: xp showed highly significant non-inferiority for pfs and significant superiority for orr vs. Fp with similar safety. These findings suggest that capecitabine should become the fluoropyrimidine of choice for agc, given the efficacy, reduced hospitalization time and simplified regimen. Xp (n=160) 95% ci fp (n=156) 95% ci p orr, % 41 33-49 29 22-37 0. 03 median pfs, months 5. 6 4. 9-7. 3 5. 0 4. 2-6. 3 0. 0001*0. 003**0. 10*** median overall survival, months 10. 5 9. 3-11. 2 9. 3 7. 4-10. 6 0. 27 *p-value for test of hr vs. Ni limit of 1. 4; **similarly with ni limit of 1. 25; ***superiority. generic viagra online overnight delivery Subgroup analyses confirmed robustness of efficacy data. buy viagra cheap   associated presentation(s):      1. Randomized phase iii trial of capecitabine/cisplatin (xp) vs. Continuous infusion of 5-fu/cisplatin (fp) as first-line therapy in patients (pts) with advanced gastric cancer (agc): efficacy and safety results meeting: 2006 asco annual meeting presenter: yoon koo kang session: gastrointestinal (non-colorectal) cancer - gastroesophageal cancer (oral abstract session)   other abstracts in this sub-category:      1. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of calgb 9781. Meeting: 2006 asco annual meeting   abstract no: 4012   first author: j. E. Tepper category: gastrointestinal (noncolorectal) cancer - esophageal, gastric, or small bowel      2. buy viagra cheap A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. mail order viagra Meeting: 2006 asco annual meeting   abstract no: 4013   first author: j. Yu category: gastrointestinal (noncolorectal) cancer - esophageal, gastric, or small bowel      3. Surgery plus elfe (epirubicin, leucovorin, 5-fluorouracil and etoposide) vs surgery alone in radically resected gastric cancer (gc): final results of a randomised phase iii trial by the gruppo oncologico dell' italia meridionale (goim). Meeting: 2006 asco annual meeting   abstract no: 4014   first author: f. order viagra online De vita category: gastrointestinal (noncolorectal) cancer - esophageal, gastric, or small bowel      more...   abstracts by y. Kang:      1. Regional differences in patient (pt) characteristics of avagast: an exploratory comparison in chemotherapy plus placebo (pl) a.